Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease

Next Previous
Trial Profile

The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cagrilintide/semaglutide (Primary)
  • Indications Cardiovascular disorders; Myocardial infarction; Peripheral arterial disorders; Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms REDEFINE 3
  • Sponsors Novo Nordisk

Most Recent Events

  • 27 Dec 2024 Status changed from recruiting to active, no longer recruiting.
  • 14 Oct 2023 Planned number of patients changed from 4000 to 7000.
  • 25 Sep 2023 Planned End Date changed from 5 May 2027 to 13 Oct 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top